We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00695786
Recruitment Status : Active, not recruiting
First Posted : June 12, 2008
Last Update Posted : February 14, 2018
Information provided by (Responsible Party):
M.D. Anderson Cancer Center